Fatigue in inflammatory bowel disease and its impact on daily activities
- PMID: 33159475
- DOI: 10.1111/apt.16145
Fatigue in inflammatory bowel disease and its impact on daily activities
Abstract
Background: Fatigue is a common symptom of chronic inflammation, including inflammatory bowel disease (IBD), resulting in significant impairment in quality of life.
Aims: To identify the prevalence of fatigue in a large IBD cohort compared to the general population, address risk factors, and evaluate its impact on daily life.
Methods: We evaluated 1208 IBD patients from the Swiss Inflammatory Bowel Disease Cohort Study (SIBDCS) and 414 healthy controls. Significant fatigue was defined as a visual analogue scale (VAS-F, range 0-10) score ≥ 4. Secondary endpoints were severity of fatigue and its impact on daily activities with the Fatigue Severity Scale (FSS), with a score ≥ 4 indicative of fatigue. Demographic, IBD-related and psychiatric symptoms were assessed with a multivariate analysis of variance (MANOVA) model optimised for prediction of VAS-F (primary outcome) and FSS scores.
Results: Overall, 672 IBD patients (55.6%) reported significant fatigue compared to 145 (35%) controls (OR 2.71; 95% CI 2.08-3.54; P < 0.001). In IBD, fatigue also significantly affected daily activities (FSS ≥ 4; 405 (33.5%) IBD patients vs 81 (19.6%) controls, P < 0.001). In the MANOVA model, fatigue levels were associated with female gender (coefficient 0.839; 0.556 - 1.123; P < 0.001), younger age at diagnosis (-0.031 per year; -0.042- -0.019; P < 0.001), shorter disease duration (-0.036 per year; -0.050- -0.022; P < 0.001), nocturnal diarrhoea (0.718; 0.295-1.141; P = 0.001), low educational level (P = 0.034) and symptoms of depression and anxiety.
Conclusions: Fatigue is both more frequent and more severe in patients with IBD than in the general population.
© 2020 John Wiley & Sons Ltd.
Comment in
-
Editorial: fatigue-difficult to assess and difficult to treat. Authors' reply.Aliment Pharmacol Ther. 2021 Jan;53(2):340-341. doi: 10.1111/apt.16190. Aliment Pharmacol Ther. 2021. PMID: 33368508 No abstract available.
-
Editorial: fatigue-difficult to assess and difficult to treat.Aliment Pharmacol Ther. 2021 Jan;53(2):339. doi: 10.1111/apt.16178. Aliment Pharmacol Ther. 2021. PMID: 33368523 No abstract available.
References
REFERENCES
-
- Elsehety A, Bertorini TE. Neurologic and neuropsychiatric complications of Crohn's disease. South Med J. 1997;90:606-610.
-
- Poynard T, Cacoub P, Ratziu V, et al. Fatigue in patients with chronic hepatitis C. J Viral Hepat. 2002;9:295-303.
-
- Overman CL, Kool MB, Da Silva JA, Geenen R. The prevalence of severe fatigue in rheumatic diseases: an international study. Clin Rheumatol. 2016;35:409-415.
-
- Campos MP, Hassan BJ, Riechelmann R, Del Giglio A. Cancer-related fatigue: a review. Rev Assoc Med Bras. 2011;57:211-219.
-
- Arnaud L, Gavand PE, Voll R, et al. Predictors of fatigue and severe fatigue in a large international cohort of patients with systemic lupus erythematosus and a systematic review of the literature. Rheumatology. 2019;58(6):987-996.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources